Oculis
ExitedOculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Total raised
€237M
€237,238,654
Funding rounds
5
Investors
14
distinct backers
Active since
2018-12
latest 2025-08
Funding by year
EUR raised per yearFunding rounds
5 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-13 | Debt | €106M | BlackRock | View deal → |
| 2024-04-12 | Other | €55M | Existing investors | View deal → |
| 2023-02-06 | Other | €14M | — | View deal → |
| 2021-05-05 | Series C | €48M | Bay City Capital,Brunnur Ventures,BVCF Management,Earlybird,Hyfinity Investments,Nan Fung Life Sciences+6 more | View deal → |
| 2019-01-01 | Series B | €14M | Tekla Capital Management | View deal → |
Exit
Type
ipo
Date
Oct 2022
Value
€82M
Acquiror
—
Investors
14Related news
- Oculis raises an additional $15M in funding before going publicnorthstack.is · 2023-02
- Oculis raises $80M and goes public through a SPAC mergernorthstack.is · 2022-10
- siliconcanals.com
- eu-startups.com
- finsmes.com
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy